menu
    • menu
    [{"orgOrder":0,"company":"Evon Medics","sponsor":"National Institute of Neurological Disorders and Stroke | Howard University | Global Pain Management | Georgetown University | University of Maryland | Johns Hopkins University | Family and Medical Counseling Service","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Beta-Caryophyllene","moa":"Cannabinoid receptor 2 (CB2)","graph1":"Neurology","graph2":"Phase II","graph3":"Evon Medics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evon Medics \/ National Institute of Neurological Disorders and Stroke | Howard University | Global Pain Management | Georgetown University | University of Maryland | Johns Hopkins University | Family and Medical Counseling Service","highestDevelopmentStatusID":"8","companyTruncated":"Evon Medics \/ National Institute of Neurological Disorders and Stroke | Howard University | Global Pain Management | Georgetown University | University of Maryland | Johns Hopkins University | Family and Medical Counseling Service"}]

    Find Clinical Drug Pipeline Developments & Deals for b-caryophyllene

    Menu

    b-caryophyllene

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Evon Medics

                            Country arrow
                            AES
                            Not Confirmed

                            Evon Medics

                            Country arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Beta-Caryophyllene

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : National Institute of Neurological Disorders and Stroke | Howard University | Global Pain Management | Georgetown University | University of Maryland | Johns Hopkins University | Family and Medical Counseling Service

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of...

                            Details : Beta-Caryophyllene is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chronic Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 04, 2024

                            Lead Product(s) : Beta-Caryophyllene

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : National Institute of Neurological Disorders and Stroke | Howard University | Global Pain Management | Georgetown University | University of Maryland | Johns Hopkins University | Family and Medical Counseling Service

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth